[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0307331A - Formulações granuladas a seco de azitromicina - Google Patents

Formulações granuladas a seco de azitromicina

Info

Publication number
BR0307331A
BR0307331A BR0307331-9A BR0307331A BR0307331A BR 0307331 A BR0307331 A BR 0307331A BR 0307331 A BR0307331 A BR 0307331A BR 0307331 A BR0307331 A BR 0307331A
Authority
BR
Brazil
Prior art keywords
azithromycin
mga
pharmaceutical formulation
forms
dry granulated
Prior art date
Application number
BR0307331-9A
Other languages
English (en)
Inventor
Barbara Alice Johnson
Ernest Shing Quan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0307331A publication Critical patent/BR0307331A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçõES GRANULADAS A SECO DE AZITROMICINA". Esta invenção refere-se a uma formulação farmacêutica, na forma de um comprimido, saqueta ou pó para forma de dosagem em suspensão, a qual compreende partículas granuladas secas de uma forma não di-hidratada de azitromicina e, facultativamente, um ou mais excipientes farmaceuticamente aceitáveis. Preferivelmente, a formulação farmacêutica é um comprimido contendo entre cerca de 40%, em massa, e cerca de 85%, em massa, de azitromicina não di-hidratada. Mais preferivelmente, a formulação farmacêutica contém azitromicina não di-hidratada selecionada de entre as formas B, D, E, F, G, H, J, M, N, 0, P, Q e R, ou suas misturas. Mesmo mais preferivelmente, a invenção diz respeito a uma formulação farmacêutica em que a dosagem de azitromicina é 250 mgA, 500 mgA, 600 mgA ou 1000 mgA. A presente invenção diz ainda respeito a uma partícula de azitromicina granulada a seco, compreendendo uma forma de azitromicina, selecionada das formas D, E, F, G, H, J, M, N, 0, P, Q e R e misturas de formas não di-hidratadas e pelo menos um excipiente farmaceuticamente aceitável.
BR0307331-9A 2002-02-01 2003-01-20 Formulações granuladas a seco de azitromicina BR0307331A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35404102P 2002-02-01 2002-02-01
PCT/IB2003/000212 WO2003063838A1 (en) 2002-02-01 2003-01-20 Dry granulated formulations of azithromycin

Publications (1)

Publication Number Publication Date
BR0307331A true BR0307331A (pt) 2004-12-07

Family

ID=27663280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307331-9A BR0307331A (pt) 2002-02-01 2003-01-20 Formulações granuladas a seco de azitromicina

Country Status (18)

Country Link
US (1) US7438924B2 (pt)
EP (1) EP1478347A1 (pt)
JP (1) JP2005526020A (pt)
KR (1) KR100676025B1 (pt)
CN (1) CN1646104A (pt)
AR (1) AR038371A1 (pt)
AU (1) AU2003201146B2 (pt)
BR (1) BR0307331A (pt)
CA (1) CA2474809A1 (pt)
CO (1) CO5611118A2 (pt)
MX (1) MXPA04007427A (pt)
NO (1) NO20043644L (pt)
NZ (1) NZ534234A (pt)
PL (1) PL372394A1 (pt)
RU (1) RU2283092C2 (pt)
TW (1) TW200306865A (pt)
WO (1) WO2003063838A1 (pt)
ZA (1) ZA200405805B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
MXPA04005105A (es) * 2001-12-21 2004-08-19 Pfizer Prod Inc Formulaciones de acitromicina directamente compresibles.
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
JP3444874B1 (ja) * 2002-12-02 2003-09-08 高砂香料工業株式会社 顆粒状香料およびその製造方法
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
AP2218A (en) * 2003-12-04 2011-04-20 Pfizer Prod Inc Azithromycin dosage forms with reduced side effects
EP1691787B1 (en) 2003-12-04 2008-07-02 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CA2591923A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
PT2050447T (pt) * 2005-06-08 2018-01-17 Orion Corp Forma de dosagem oral contendo entacapona
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
TWI564033B (zh) * 2006-06-30 2017-01-01 艾修提卡股份有限公司 製造奈米微粒形式生物活性化合物之方法
EP2086512A2 (en) * 2006-10-27 2009-08-12 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
FI20070521L (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
US8568779B2 (en) 2007-01-11 2013-10-29 Kaneka Corporation Method for producing coenzyme Q10 particle
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP3326620B1 (en) 2010-12-16 2020-03-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
JP5585920B2 (ja) * 2010-12-27 2014-09-10 富田製薬株式会社 粒子状製剤
JP6022538B2 (ja) 2011-04-12 2016-11-09 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
US10335369B2 (en) 2012-03-22 2019-07-02 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
CA2868188A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
TW271400B (pt) 1992-07-30 1996-03-01 Pfizer
US5795871A (en) 1994-04-26 1998-08-18 Nobuhiro Narita Pharmaceutical composition for treatment of non-small cell lung cancer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
SK282854B6 (sk) 1994-05-06 2002-12-03 Pfizer Inc. Dávkovacia forma s riadeným uvoľňovaním obsahujúca azitromycín
CA2302010C (en) 1997-09-10 2010-11-23 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
US6339063B1 (en) 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
IL158591A0 (en) 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
WO2003032922A2 (en) * 2001-10-18 2003-04-24 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions

Also Published As

Publication number Publication date
TW200306865A (en) 2003-12-01
AR038371A1 (es) 2005-01-12
RU2004123624A (ru) 2005-04-10
JP2005526020A (ja) 2005-09-02
AU2003201146B2 (en) 2008-04-17
MXPA04007427A (es) 2004-10-11
PL372394A1 (en) 2005-07-25
CA2474809A1 (en) 2003-08-07
KR100676025B1 (ko) 2007-01-29
US20030228357A1 (en) 2003-12-11
RU2283092C2 (ru) 2006-09-10
WO2003063838A1 (en) 2003-08-07
CO5611118A2 (es) 2006-02-28
KR20040079954A (ko) 2004-09-16
EP1478347A1 (en) 2004-11-24
CN1646104A (zh) 2005-07-27
NZ534234A (en) 2007-05-31
ZA200405805B (en) 2006-05-31
US7438924B2 (en) 2008-10-21
NO20043644L (no) 2004-09-21

Similar Documents

Publication Publication Date Title
BR0307331A (pt) Formulações granuladas a seco de azitromicina
BRPI0406996A (pt) Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
TW200505506A (en) Pharmaceutical safety dosage forms
AR057636A2 (es) Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria
ES2187822T3 (es) Comprimidos de disgregacion rapida.
BR122012014331A8 (pt) Formulações farmacêuticas
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
HRP20100674T1 (hr) Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka
RS54329B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
SI2729130T1 (en) Combined formulations of darunavir
MXPA04003027A (es) Metodos para granulacion humeda de azitromicina.
AR029312A1 (es) Formas cristalinas de eto2c-ch2-(r)cgl-aze-pab-oh, procesos para su produccion, formulacion farmaceutica, y uso de estos compuestos para la elaboracion de un medicamento.
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
BR0111868A (pt) Composições farmacêuticas
HUP0500097A2 (hu) Nyújtott/szabályozott hatóanyag-leadású szilárd készítmény, mint kisebb dózisveszteséget mutató új hatóanyag-adagoló rendszer
HUP0004363A2 (hu) Miltefosint tartalmazó orális szilárd gyógyszerkészítmények leishmaniasis kezelésére
BR9809268A (pt) Unidade de dosagem farmacêutica, processo para fabricação da mesma, e, uso de um produto de amido como um veìculo para unidades de dosagem farmacêutica compreendendo tibolona
SV2002000574A (es) Composicion de eletriptan en forma de particulas ref. pcs10915aajr/bb

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.